Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abnormally, ACE, acknowledging, adjudicated, AKAVA, AMP, angiotensin, antibody, arm, ASP, attached, bill, Biohaven, biomarker, body, Boehringer, bpm, breath, breathe, breathing, Bristol, burdensome, camzyostm, car, cautioned, cGDP, channel, climate, Coadministration, comercializaation, context, Cooley, copay, cord, CRL, crossover, crowded, dearth, deeper, degenerative, Delinquent, diagnosed, diaphragm, eating, eccentric, Edgewise, elevated, Eleven, enzyme, everyday, excise, exhaustive, explained, expressly, extinguishment, Facebook, fainting, Ferrer, Fisher, forfeited, freestanding, Gehrig, Gilead, guideline, harrington, hemodynamic, hereto, Imbria, Ingelheim, inquiry, inside, Instagram, interventricular, involuntary, IRA, landscape, leaflet, lessen, LinkedIn, Lou, lt, LVOT, MAA, meant, Metoprolol, Mineralocorticoid, mitral, moment, monotherapy, myocardium, Nephrology, nerve, network, nondihydropyridine, older, operationalize, pain, Pennsylvania, persuasive, prohormone, purported, push, pushed, PY, Radnor, rapidly, Ratification, readmission, recurrence, regurgitation, reinstituted, relax, relaxation, Relyvriotm, remodeling, renamed, resistant, RR, SAM, SE, Secretary, semiannually, septum, serialized, standing, steadily, stepwise, stiffer, subset, Tenaya, Thermo, thick, thickening, tool, TriCare, tripartite, Twitter, Unconstrained, undue, unduly, Valsalva, valve, vehicle, ventricle, wall, withdrew, worsening, YouTube
Removed:
accrete, acting, activate, acute, adding, adequacy, aerobic, ambulatory, analogue, aspect, assumed, beneficially, biochemical, capability, capture, cardiomyopathy, category, ceftriaxone, characterize, charge, commit, Commonwealth, complicated, contra, controlling, correlated, creatine, curtail, de, dexpramipexole, discomfort, disproportionate, Distance, diversion, domain, elderly, EMPOWER, encouraging, endurance, esq, exclusively, exercisable, Exh, existed, Expiratory, failed, feeling, filtration, forced, forward, gage, glomerular, Hammersmith, heavily, hedge, Herewith, HFSA, hot, infarction, influencing, Institut, institution, interpreting, intraperiod, inventory, invest, investee, judged, Kilroy, kinase, latitude, learned, Les, letter, Limb, mark, maximal, MB, MEP, Minute, Mitigation, Module, month, mouse, negotiation, netted, Neurological, notification, nusinersen, olesoxime, onasemnogene, originally, patrick, perception, PHD, Philadelphia, physicochemical, practicable, programming, PROM, PTC, Questionnaire, Regeneron, remediated, risdiplam, Roche, Russia, SA, safely, Sanofi, Schlossberg, selectively, sensitivity, Servier, SMN, specificity, SPINRAZA, Stealth, sublicense, subsidiary, suggest, suit, Symposium, Timed, tirasemtiv, titrated, traded, train, unchanged, unpartnered, unrelated, unremediated, urgency, vendor, verification, viability, Walk, warrant, Zolgensma
Filing tables
Filing exhibits
- 10-K Annual report
- 4.6 EX-4.6
- 4.9 EX-4.9
- 5.1 EX-5.1
- 10.5 EX-10.5
- 10.9 EX-10.9
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.28 EX-10.28
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 31.3 EX-31.3
- 32.1 EX-32.1
- Download Excel data file
- View Excel data file
Related press release
Associated CYTK transcripts
CYTK similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1)
Registration Statements (Form S-3 Nos. 333-234537, and 333-268483) of Cytokinetics, Incorporated, and
2)
Registration Statements (Form S-8 Nos. 333-115146, 333-125973, 333-133323, 333-136524, 333-140963, 333-149713, 333-152850, 333-161116, 333-168520, 333-176089, 333-183091, 333-190458, 333-206101, 333-221348, 333-236889, 333-238786, 333-256054, 333-260840 and 333-265316) pertaining to the Amended and Restated 2004 Equity Incentive Plan of Cytokinetics, Incorporated;
of our reports dated March 1, 2023, with respect to the consolidated financial statements of Cytokinetics, Incorporated and the effectiveness of internal control over financial reporting of Cytokinetics, Incorporated included in this Annual Report (Form 10-K) of Cytokinetics, Incorporated for the year ended December 31, 2022.
/s/ Ernst & Young LLP
San Mateo, California
March 1, 2023